Canopy Growth Corp
TSX:WEED
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/FCFF
Enterprise Value to Free Cash Flow to Firm (EV/FCFF) ratio compares a company`s total enterprise value to the free cash flow available to all investors, both debt and equity holders. It shows how much investors are paying for each dollar of cash flow the business generates before interest payments.
Enterprise Value to Free Cash Flow to Firm (EV/FCFF) ratio compares a company`s total enterprise value to the free cash flow available to all investors, both debt and equity holders. It shows how much investors are paying for each dollar of cash flow the business generates before interest payments.
Valuation Scenarios
If EV/FCFF returns to its Industry Average (14.4), the stock would be worth CA$-3.74 (332% downside from current price).
| Scenario | EV/FCFF Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | -6.2 | CA$1.61 |
0%
|
| Industry Average | 14.4 | CA$-3.74 |
-332%
|
| Country Average | 20.4 | CA$-5.3 |
-429%
|
Forward EV/FCFF
Today’s price vs future free cash flow to firm
Peer Comparison
| Market Cap | EV/FCFF | P/E | ||||
|---|---|---|---|---|---|---|
| CA |
|
Canopy Growth Corp
TSX:WEED
|
747.6m CAD | -6.2 | -1.8 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
825.8B USD | 144 | 40 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
548.5B USD | 29.2 | 26.1 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 26.4 | 20.1 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
215.6B GBP | 34.9 | 27.6 | |
| CH |
|
Novartis AG
SIX:NOVN
|
218.9B CHF | 19.3 | 19.8 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
272.3B USD | 24.6 | 14.9 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
244.4B USD | 1 486.8 | -83.6 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.2T DKK | 43.2 | 11.4 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
150.6B USD | 21.9 | 19.4 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
117.3B USD | 11.7 | 16.6 |
Market Distribution
| Min | 0 |
| 30th Percentile | 13.1 |
| Median | 20.4 |
| 70th Percentile | 33.5 |
| Max | 22 577.3 |
Other Multiples
Canopy Growth Corp
Glance View
Canopy Growth Corp. engages in the production and sale of medical cannabis. The company is headquartered in Smiths Falls, Ontario and currently employs 3,259 full-time employees. The company went IPO on 2010-06-04. The firm operates through two segments: Global Cannabis and Other Consumer Products. The Global Cannabis segment encompasses the production, distribution and sale of a diverse range of cannabis and cannabinoid-based consumer products in Canada and internationally pursuant to applicable international and domestic legislation, regulations and permits. The Other Consumer Products segment comprises the production, distribution and sale of consumer products, including Storz & Bickel vaporizers; This Works beauty, skincare, wellness and sleep products; BioSteel sports nutrition beverages, mixes, protein, gum and mints; and other revenue sources.
